Price
No data yet.
Social Signal Score
Analyst Ratings
49 analystsRevenue
$1.72B+123.46%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Bernard J. Zovighian
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 16,000
- Beta
- 0.83
- Country
- US
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 13.83
Financials
Revenue
$1.72B+123.5%Net Income
$307.50M+94.0%EBITDA
$408.10M+78.9%Free Cash Flow
$506.70M+267.4%EPS (diluted)
$0.53+120.8%Shares Outstanding (diluted)
577.60M-11.6%Operating Expenses
$842.30MCash & Debt
$4.64BReturn of Capital
$138.90MRevenue by Segment (annual)
$6.07BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $6.07B | $1.07B | $1.84 |
| 2024 | $5.44B | $4.17B | $6.98 |
| 2023 | $5.01B | $1.40B | $2.31 |
| 2022 | $5.38B | $1.52B | $2.46 |
| 2021 | $5.23B | $1.50B | $2.41 |
| 2020 | $4.39B | $823.40M | $1.32 |
| 2019 | $4.35B | $1.05B | $1.68 |
| 2018 | $3.72B | $722.20M | $1.15 |
| 2017 | $3.44B | $622.10M | $0.98 |
| 2016 | $2.96B | $569.50M | $0.89 |
| 2015 | $2.49B | $494.90M | $0.77 |
| 2014 | $2.32B | $811.10M | $1.27 |
| 2013 | $2.05B | $391.70M | $0.59 |
| 2012 | $1.90B | $293.20M | $0.43 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from EW's reported EPS growth of 11.8% a year over 13 years.
- EPS in 5 years
- $3.21
- Implied price
- $147.49
- Return from $101.85
- 7.7% a year
To earn 15.0% a year on these assumptions you'd need to buy at $73.33 — -28.0% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 32 | 39 | 46 | 53 | 60 |
|---|---|---|---|---|---|
| 1.8% | -8.8% | -5.1% | -1.9% | 0.9% | 3.4% |
| 6.8% | -4.3% | -0.5% | 2.9% | 5.8% | 8.5% |
| 11.8% | 0.1% | 4.2% | 7.7% | 10.8% | 13.6% |
| 16.8% | 4.6% | 8.8% | 12.5% | 15.7% | 18.6% |
| 21.8% | 9.1% | 13.5% | 17.3% | 20.7% | 23.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-23.08%Social Signal Score
Mentions (38)
- News (RSS)seekingalpha·4d ago·Neutral
Edwards Lifesciences: Momentum Returns, But Valuation Warrants Caution
View source ↗ - 4chan /biz/biz·10d ago·Positive
>>62893848 How. They can just finish of the EW pipeline and fully blockade Saudi ships. Or better yet. Just destroy the port pumping infrastructure
View source ↗ - News (RSS)investing·11d ago·Neutral
Edwards Lifesciences stock hits 52-week high at 105.39 USD
View source ↗ - News (RSS)zerohedge·14d ago·Neutral
Drones Built To Look Like Birds Evaded Detection At Air Force Tech Exercise Drones Built To Look Like Birds Evaded Detection At Air Force Tech Exercise Authored by Patty Nieberg via Task & Purpose,A wing-flapping drone appearing to fly like a bird evaded sensor detection at a recent Air Force tech exercise in the Mojave Desert. Mimicking a crow in shape and profile, Ornadyne's O1 launches during an evaluation during "Game of Drones" at Edwards Air Force Base, Sept. 17, 2026. Air Force photo by J
View source ↗ - Newsmarketbeat.com·15d ago·Neutral
Edwards Lifesciences Q3 Earnings Call Highlights Edwards Lifesciences NYSE: EW raised its 2026 sales and earnings guidance after third-quarter results exceeded management's expectations, with growth across its heart-valve businesses and regions.
View source ↗ - Newszacks.com·17d ago·Positive
Edwards Q3 Earnings & Revenues Surpass Estimates, Stock Climbs EW tops Q3 earnings and revenue estimates as strong structural heart therapy sales drive margin expansion and prompt higher 2026 guidance.
View source ↗ - Newsseekingalpha.com·18d ago·Positive
Edwards Lifesciences Corporation (EW) Q3 2026 Earnings Call Transcript Edwards Lifesciences Corporation (EW) Q3 2026 Earnings Call Transcript
View source ↗ - News (RSS)businessinsider·18d ago·Negative
New Research Suggests hERG IC₁₀ May Improve Prediction of Drug-Induced QT Prolongation <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" />NEW ORLEANS, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Dr. William J. Crumb Jr., Ph.D., President and CEO of Nova Research Laboratories, LLC, has collaborated with Dr. Andrew G. Edwards, Ph.D., Chief Research Scientist of Simula Research Laboratory in...
View source ↗ - News (RSS)economictimes·18d ago·Positive
… by electronic fuzes worth Rs 4,200 crore, LCA Mk1 at Rs 3,200 crore, LRSAM at Rs 2,900 crore, BMP-2 upgrades at Rs 2,600 crore, Ashwini radar at Rs 2,500 crore, the EW suite for Mi-17 at Rs 2,200 crore and an export order worth Rs 1,700 crore. Together, these seven programmes account for around Rs 19,300 crore of the order book.Excluding electronic fuzes, which have another six to seven years of execution remaining, most of these orders are expected to be completed over the next 3-3.5 years. Mo…
View source ↗ - News (RSS)seekingalpha·19d ago·Positive
Edwards Lifesciences Corporation (EW) Discusses CLASP II TR and PROGRESS Trial Results in Tricuspid and TAVR Transcript
View source ↗ - Newsseekingalpha.com·19d ago·Positive
Edwards Lifesciences Corporation (EW) Discusses CLASP II TR and PROGRESS Trial Results in Tricuspid and TAVR Transcript Edwards Lifesciences Corporation (EW) Discusses CLASP II TR and PROGRESS Trial Results in Tricuspid and TAVR Transcript
View source ↗ - Newsmarketbeat.com·19d ago·Positive
Edwards Lifesciences Highlights PASCAL, TAVR Data Showing Patient Benefits Edwards Lifesciences NYSE: EW highlighted new clinical data for its transcatheter tricuspid repair and transcatheter aortic valve replacement programs, including results from the CLASP IITR trial of the PASCAL system and the PROGRESS trial evaluating TAVR in certain patients with moderate aortic stenosis. Get Edwards Lifesciences alerts:Sign UpCLASP IITR meets six-month primary endpoint Charlie Davidson, chief of cardiolo…
View source ↗ - Newsbusinesswire.com·20d ago·Neutral
…P II TR Trial Demonstrates Superior Clinical, Quality-of-Life Benefits With Edwards PASCAL System SAN DIEGO--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced that the PASCAL system for tricuspid repair demonstrated superiority compared to medical therapy alone for the six-month primary endpoint of the CLASP II TR trial. The evidence further showed significant reduction of tricuspid regurgitation (TR) and substantially improved health status, both sustained through one…
View source ↗ - Newsbusinesswire.com·20d ago·Positive
…Demonstrates Edwards TAVR Is Superior to Clinical Surveillance for Moderate AS Patients With At-Risk Features SAN DIEGO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced results from the PROGRESS Trial, marking a turning point in the management of moderate aortic stenosis (AS). The trial demonstrated that transcatheter aortic valve replacement (TAVR) was superior to clinical surveillance in the primary composite endpoint of death or heart failure events at two years in moderate A…
View source ↗ - Newszacks.com·23d ago·Neutral
Edwards' Q3 Earnings on the Horizon: What's in the Cards? Edwards Lifesciences Corp. EW is scheduled to report third-quarter 2026 results on Nov. 4, after the market closes.
View source ↗ - Newszacks.com·23d ago·Neutral
Curious about Edwards Lifesciences (EW) Q3 Performance? Explore Wall Street Estimates for Key Metrics Beyond analysts' top-and-bottom-line estimates for Edwards Lifesciences (EW), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2026.
View source ↗ - Newsseekingalpha.com·24d ago·Neutral
Edwards Lifesciences Continually Innovating Ahead Of Q3 Results, Cardio Portfolio Thrives Edwards Lifesciences gets a buy for my initial rating. Strengths come from recent FDA approvals, a niche portfolio serving the cardiology segment, and impressive operating margins and operating cash flow. EW's price return vs. key benchmarks showed weakness this year.
View source ↗ - 4chan /biz/biz·27d ago·Negative
>>62820522 Well I'm already retired, but I would like some more money to hire hookers and stuff >>62820525 Yes I also post the EW chart each thread and often >futures post
View source ↗ - 4chan /biz/biz·30d ago·Neutral
>>62809857 lets see if it makes the EW weekly graphic tomorrow
View source ↗ - 4chan /biz/biz·30d ago·Neutral
>>62809850 EW will publish the next week's daily chart tomorrow
View source ↗ - Newszacks.com·31d ago·Positive
Is This the Right Time to Hold EW Stock in Your Portfolio? Edwards Lifesciences' TMTT and TAVR growth, strong clinical evidence and solid balance sheet support expansion, but tariffs and currency headwinds threaten margins.
View source ↗ - News (RSS)zerohedge·34d ago·Negative
Geothermal Just Undercut Solar-Plus-Storage In Sunny Nevada Geothermal Just Undercut Solar-Plus-Storage In Sunny Nevada Geothermal has long been the clean, firm power source that was always a few breakthroughs away from being cheap enough to matter. Numbers buried in a Nevada utility filing suggest that day may have arrived. Joel Edwards, co-founder and CTO of geothermal developer Zanskar, put it bluntly earlier this month: "to all the geothermal believers out there, the flippening has come." to
View source ↗ - Newsbusinesswire.com·48d ago·Neutral
Edwards Lifesciences to Host Investor Event in Conjunction With TCT IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that it will host an investor event in conjunction with the TCT annual scientific symposium in San Diego on Monday, Nov. 2, from 5:00 to 6:00 PM Pacific Time. The meeting will include a live Q&A session with physicians and members of the Edwards management team. A live webcast of the event will be available on the Edwards Lifesciences investor relat…
View source ↗ - 4chan /biz/biz·56d ago·Neutral
>>62730530 >most of the oil is being routed around it now This is nonsense because Hootie and the blow fish are blocking bab el mandeb and hitting their EW pipeline facilities. This is all propaganda.
View source ↗ - Newsmarketbeat.com·66d ago·Neutral
Edwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity Ahead Edwards Lifesciences NYSE: EW outlined a strategy centered on structural heart disease, with Chief Executive Officer Bernard Zovighian highlighting five therapy areas that the company views as its principal growth platforms: transcatheter aortic valve replacement for aortic stenosis, PASCAL, EVOQUE, SAPIEN M3 and surgical therapies.
View source ↗ - Newsseekingalpha.com·67d ago·Positive
Edwards Lifesciences Corporation (EW) Presents at Deutsche Bank 2026 Healthcare Summit Transcript Edwards Lifesciences Corporation (EW) Presents at Deutsche Bank 2026 Healthcare Summit Transcript
View source ↗ - News (RSS)seekingalpha·73d ago·Positive
Edwards Lifesciences praises CMS NCD on transcatheter aortic valve replacement
View source ↗ - Newsbusinesswire.com·73d ago·Positive
Edwards Lifesciences Comments on TAVR National Coverage Decision IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today issued the following statement in response to the national coverage determination (NCD) for transcatheter aortic valve replacement (TAVR) released by the Centers for Medicare & Medicaid Services (CMS):“Edwards is pleased that this updated policy represents an important step toward improving and expanding patient access to TAVR while reinforcing the value of a mu…
View source ↗ - News (RSS)seekingalpha·75d ago·Neutral
Baron Asset Fund adds CBRS and EW; exits FICO and FND
View source ↗ - News (RSS)seekingalpha·76d ago·Neutral
Edwards Lifesciences: $20 Billion TAM And A Meaningful Opportunity To Compound
View source ↗ - News (Marketaux)seekingalpha.com·76d ago·Positive
Edwards Lifesciences: $20 Billion TAM And A Meaningful Opportunity To Compound (NYSE:EW) Edwards Lifesciences: $20 Billion TAM And A Meaningful Opportunity To Compound (NYSE:EW)
View source ↗ - PodcastCompound And Friends·89d ago·Positive
is like Edwards and McGee stuff, but basically you would take the amount of the move that preceded it, and then on the other side, that's how far you should expect this to be able to keep running before it runs out of steam, so these are very bullish, this thing gapped up and never even looked back at that gap level, Michael, would you agree that's a pretty bullish formation in a chart, insanely, okay, management is now guiding to a fifth consecutive quarter of 10% or higher growth in usage, so
View source ↗ - News (RSS)zerohedge·91d ago·Neutral
…. Stout Stryker air artillery Mission Equipment Package). Dr. Smith outlined a layered approach beginning with Radio Frequency (RF) detection and Electronic Warfare (EW) at standoff ranges, then lasers for cost-effective engagement within line-of-sight, and kinetic interceptors when necessary. Speakers emphasized mobility and integrated C2 so that different defeat mechanisms can be applied as threats evolve, reflecting a pragmatic view that no single technology will defeat every class of drone. …
View source ↗ - Newszacks.com·94d ago·Neutral
Should You Hold Edwards Lifesciences Stock in Your Portfolio? EW's TAVR and TMTT growth support its outlook, but currency pressure and intense competition remain key risks.
View source ↗ - Newszacks.com·100d ago·Positive
Is EW Stock Worth Buying as Growth Clashes With a Premium Valuation? Edwards Lifesciences pairs accelerating structural heart growth and stronger leverage with a premium valuation that leaves less room for execution setbacks.
View source ↗ - Newszacks.com·101d ago·Positive
Edwards Climbs 14% in 3 Months as Growth Strength Tests Valuation Edwards' 14% three-month rally reflects broad structural-heart growth, but its premium valuation raises the bar for execution.
View source ↗ - News (RSS)yahoo·102d ago·Neutral
Is Wall Street Bullish or Bearish on Edwards Lifesciences Stock?
View source ↗ - News (Marketaux)seekingalpha.com·102d ago·Neutral
Edwards Lifesciences: Cheap Against Itself, Expensive Against Everything Else (NYSE:EW) Edwards Lifesciences: Cheap Against Itself, Expensive Against Everything Else (NYSE:EW)
View source ↗
Earnings
Tue, Feb 9(in 3 months)
Consensus estimate $0.66 per share
Typical surprise +7.4% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Nov 4$0.80 vs $0.74beat
- Thu, Jul 23$0.78 vs $0.74beat
- Thu, Apr 23$0.78 vs $0.73beat
- Tue, Feb 10$0.58 vs $0.62miss
- Thu, Oct 30$0.67 vs $0.60beat
- Thu, Jul 24$0.67 vs $0.62beat
Estimates and results for EW via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by EW officers and directors.
- Bought
- —
- Sold
- $18.8m
0 trades
27 trades
- Lippis Daniel J.sold
- Zovighian Bernard Jsold
- Zovighian Bernard Jsold
- Bobo Donald E Jrsold
- Lippis Daniel J.sold
- Lippis Daniel J.sold
- Dahl Andrew M.sold
- Bruls Annettesold
73 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 11, 2026 (41d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 10, 2026 (28d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Dec 30, 2025 (41d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 14, 2025 (38d later)Sell$1,001 - $15,000
- Jefferson Shrevehouse · IN06 · disclosed Jun 23, 2025 (42d later)Sell$50,001 - $100,000
- Bruce Westermanhouse · AR04 · disclosed May 13, 2025 (22d later)Sell$1,001 - $15,000
- Jefferson Shrevehouse · IN06 · disclosed May 9, 2025 (32d later)Buy$15,001 - $50,000
- Robert P. Bresnahanhouse · PA08 · disclosed May 8, 2025 (30d later)Buy$1,001 - $15,000
- Bruce Westermanhouse · AR04 · disclosed Apr 17, 2025 (45d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 11, 2024 (28d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 8, 2024 (29d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 8, 2024 (29d later)Buy$1,001 - $15,000
- Markwayne Mullinsenate · OK · disclosed Sep 19, 2024 (30d later)Sell$15,001 - $50,000
- Mike Kellyhouse · PA16 · disclosed Jun 14, 2024 (64d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Mar 6, 2024 (22d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jan 7, 2024 (27d later)Buy$1,001 - $15,000
- John R. Curtishouse · UT03 · disclosed Dec 15, 2023 (11d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Dec 6, 2023 (33d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 8, 2023 (13d later)Sell$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
